Bronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers with asthma.
Clin Pharmacol Ther
; 86(1): 49-53, 2009 Jul.
Article
em En
| MEDLINE
| ID: mdl-19357642
ABSTRACT
Smokers with asthma show a reduced response to inhaled corticosteroids. We hypothesized that a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist would be superior for the clinical treatment of these asthma patients. Forty-six smokers with asthma were randomized to inhaled beclometasone dipropionate (200 microg per day) or rosiglitazone (8 mg per day) for 4 weeks. Rosiglitazone produced improvements in lung function (forced expiratory volume in 1 s (FEV(1)) = 183 ml, P = 0.051; forced expiratory flow between 25 and 75% of the forced vital capacity (FEF(25-75)) = 0.24 l/s, P = 0.030) as compared with inhaled beclometasone dipropionate. Further trials using PPAR-gamma agonists in steroid-resistant airway disease are indicated.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Asma
/
Broncodilatadores
/
Fumar
/
Tiazolidinedionas
/
PPAR gama
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article